UBR5 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 2.35589325825458E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
2.85229999952286E-07 |
Normal-vs-Stage2 |
7.216500E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
7.498700E-03 |
Stage1-vs-Stage2 |
9.563200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.999400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
9.675200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.0180968835225E-11 |
Normal-vs-AfricanAmerican |
2.392400E-01 |
Normal-vs-Asian |
1.295780E-02 |
Caucasian-vs-AfricanAmerican |
6.048000E-02 |
Caucasian-vs-Asian |
9.627200E-01 |
AfricanAmerican-vs-Asian |
2.243200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
2.2645999999682E-06 |
Normal-vs-Female |
1.12549999986555E-07 |
Male-vs-Female |
4.566000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.392900E-04 |
Normal-vs-Extreme_Weight |
4.76220000000804E-06 |
Normal-vs-Obese |
1.100410E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
7.472000E-02 |
Normal_Weight-vs-Obese |
7.626100E-02 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
7.838000E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.545000E-01 |
Normal-vs-Age(41-60Yrs) |
6.565700E-04 |
Normal-vs-Age(61-80Yrs) |
8.14709999463759E-09 |
Normal-vs-Age(81-100Yrs) |
3.887000E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.671200E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.239800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.230200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.392800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.794800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.744800E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
3.031800E-01 |
Normal-vs-Grade 3 |
2.520600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
7.566200E-01 |
Grade 2-vs-Grade 4 |
3.031800E-01 |
Grade 3-vs-Grade 4 |
2.520600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.19280005264721E-09 |
Normal-vs-N1 |
1.717670E-02 |
N0-vs-N1 |
4.994800E-01 |
|
|